---
title: "Humira (adalimumab) in rheumatoid arthritis: Clinical trials questions"
description: "Clinical trials questions on Humira (adalimumab) in rheumatoid arthritis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results and Long-term results. Questions: How effective is Humira vs placebo for rheumatoid arthritis (ACR response)? How much does Humira reduce tender and swollen joints in RA? Does Humira work when added to standard RA therapy (Study RA-IV)? How effective is Humira plus methotrexate vs methotrexate in early RA (PREMIER)? 5 further questions follow. 9 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Humira (adalimumab) in rheumatoid arthritis: Clinical trials questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Humira](https://www.rxabbvie.com/pdf/humira.pdf)

Questions that apply to every indication of Humira are on [Humira (adalimumab), all indications](https://www.evicenter.com/medical-information/humira).

## Study results

<a id="humira-ra-acr-response"></a>

### How effective is Humira vs placebo for rheumatoid arthritis (ACR response)?

> “Study RA-I evaluated 271 subjects who had failed therapy with at least one but no more than 
> four DMARDs and had inadequate response to MTX. Doses of 20, 40 or 80 mg of HUMIRA or 
> placebo were given every other week for 24 weeks.  
> Study RA-II evaluated 544 subjects who had failed therapy with at least one DMARD. Doses of 
> placebo, 20 or 40 mg of HUMIRA were given as monotherapy every other week or weekly for 
> 26 weeks.  
> Study RA-III evaluated 619 subjects who had an inadequate response to MTX. Subjects received 
> placebo, 40 mg of HUMIRA every other week with placebo injections on alternate weeks, or 20 
> mg of HUMIRA weekly for up to 52 weeks. Study RA-III had an additional primary endpoint at 
> 52 weeks of inhibition of disease progression (as detected by X-ray results). Upon completion of 
> the first 52 weeks, 457 subjects enrolled in an open-label extension phase in which 40 mg of 
> HUMIRA was administered every other week for up to 5 years.”

Source: [HUMIRA: Prescribing information, page 32, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=32)

> “Table 3. ACR Responses in Studies RA-II and RA-III (Percent of Subjects) 
>
> Study RA-II 
> Monotherapy 
> (26 weeks) 
> Study RA-III 
> Methotrexate Combination 
> (24 and 52 weeks) 
> Response 
> Placebo 
> HUMIRA 
> HUMIRA 
> Placebo/MTX 
> HUMIRA/MTX 
>
>
> 40 mg every  
> 40 mg weekly   
> 40 mg every 
>
>
>  other week   
>
> other week 
>
> N=110 
> N=113 
> N=103 
> N=200 
> N=207 
> ACR20 
>
>
>
>
>
> Month 6 
> 19% 
> 46%* 
> 53%* 
> 30% 
> 63%* 
> Month 12 
> NA 
> NA 
> NA 
> 24% 
> 59%* 
> ACR50 
>
>
>
>
>
> Month 6 
> 8% 
> 22%* 
> 35%* 
> 10% 
> 39%* 
> Month 12 
> NA 
> NA 
> NA 
> 10% 
> 42%* 
> ACR70 
>
>
>
>
>
> Month 6 
> 2% 
> 12%* 
> 18%* 
> 3% 
> 21%* 
> Month 12 
> NA 
> NA 
> NA 
> 5% 
> 23%* 
> * p<0.01, HUMIRA vs. placebo”

Source: [HUMIRA: Prescribing information, page 33, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=33)

> “The results of Study RA-I were similar to Study RA-III; subjects receiving HUMIRA 40 mg 
> every other week in Study RA-I also achieved ACR 20, 50 and 70 response rates of 65%, 52% 
> and 24%, respectively, compared to placebo responses of 13%, 7% and 3% respectively, at 6 
> months (p<0.01).”

Source: [HUMIRA: Prescribing information, page 33, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=33)

Note: Table 3 columns are, in order: Study RA-II (monotherapy, 26 weeks) placebo, HUMIRA 40 mg every other week, and HUMIRA 40 mg weekly; then Study RA-III (methotrexate combination) placebo/MTX and HUMIRA/MTX 40 mg every other week.

<a id="humira-ra-tender-swollen-joints"></a>

### How much does Humira reduce tender and swollen joints in RA?

> “Table 4. Components of ACR Response in Studies RA-II and RA-III 
>
> Study RA-II 
> Study RA-III 
> Parameter (median) 
> Placebo 
> N=110 
> HUMIRA<sup>a</sup> 
> N=113 
> Placebo/MTX 
> N=200 
> HUMIRA<sup>a</sup>/MTX  
> N=207 
>
> Baseline Wk 
> 26 
> Baseline Wk 
> 26 
> Baseline Wk 24 Baseline 
> Wk 24 
> Number of tender 
> joints (0-68) 
> 35 
> 26 
> 31 
> 16* 
> 26 
> 15 
> 24 
> 8*”

Source: [HUMIRA: Prescribing information, page 33, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=33)

> “Number of swollen 
> joints (0-66) 
> 19 
> 16 
> 18 
> 10* 
> 17 
> 11 
> 18 
> 5* 
> Physician global 
> assessment<sup>b</sup> 
> 7.0 
> 6.1 
> 6.6 
> 3.7* 
> 6.3 
> 3.5 
> 6.5 
> 2.0* 
> Patient global 
> assessment<sup>b</sup> 
> 7.5 
> 6.3 
> 7.5 
> 4.5* 
> 5.4 
> 3.9 
> 5.2 
> 2.0* 
> Pain<sup>b</sup> 
> 7.3 
> 6.1 
> 7.3 
> 4.1* 
> 6.0 
> 3.8 
> 5.8 
> 2.1* 
> Disability index 
> (HAQ)<sup>c</sup> 
> 2.0 
> 1.9 
> 1.9 
> 1.5* 
> 1.5 
> 1.3 
> 1.5 
> 0.8* 
> CRP (mg/dL) 
> 3.9 
> 4.3 
> 4.6 
> 1.8* 
> 1.0 
> 0.9 
> 1.0 
> 0.4* 
> <sup>a</sup> 40 mg HUMIRA administered every other week 
> <sup>b</sup> Visual analogue scale; 0 = best, 10 = worst 
> <sup>c</sup> Disability Index of the Health Assessment Questionnaire; 0 = best, 3 = worst, measures the 
> patient’s ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain 
> hygiene, and maintain daily activity 
> * p<0.001, HUMIRA vs. placebo, based on mean change from baseline”

Source: [HUMIRA: Prescribing information, page 34, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=34)

Note: Table 4 continues from page 33 to page 34 of the Prescribing Information. Each row gives the median at baseline and at Week 26 (Study RA-II) or Week 24 (Study RA-III), in the order placebo, HUMIRA, placebo/MTX, HUMIRA/MTX.

<a id="humira-ra-with-other-dmards"></a>

### Does Humira work when added to standard RA therapy (Study RA-IV)?

> “Study RA-IV assessed safety in 636 subjects who were either DMARD-naive or were permitted 
> to remain on their pre-existing rheumatologic therapy provided that therapy was stable for a 
> minimum of 28 days. Subjects were randomized to 40 mg of HUMIRA or placebo every other 
> week for 24 weeks.”

Source: [HUMIRA: Prescribing information, page 32, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=32)

> “In Study RA-IV, 53% of subjects treated with HUMIRA 40 mg every other week plus standard 
> of care had an ACR 20 response at week 24 compared to 35% on placebo plus standard of care 
> (p<0.001). No unique adverse reactions related to the combination of HUMIRA (adalimumab) 
> and other DMARDs were observed.”

Source: [HUMIRA: Prescribing information, page 34, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=34)

<a id="humira-premier-acr50"></a>

### How effective is Humira plus methotrexate vs methotrexate in early RA (PREMIER)?

Applies to: Adults with early moderate to severe rheumatoid arthritis (less than 3 years' duration) who had not received methotrexate (PREMIER, Study RA-V)

> “PREMIER study design intro: 2-year, double-blind, active comparator-controlled study of adult patients with early moderate to severe RA (<3 years’ duration) and who were MTX-naïve. 799 patients were randomized to receive HUMIRA 40 mg EOW + MTX weekly (n=268), HUMIRA 40 mg EOW (n=274), or MTX weekly (n=257). Co-primary endpoints were ACR50 response and change from baseline in mTSS at Week 52.<sup>1,2</sup>”

Source: [HUMIRA: HUMIRA® (adalimumab) for Rheumatoid Arthritis (RA), captured 2026-11-13](https://www.humirapro.com/rheumatoid-arthritis#:~:text=PREMIER%20study%20design%20intro%3A%202%2Dyear%2C,baseline%20in%20mTSS%20at%20Week)

> “Signs and symptoms: ACR50 response rates at Weeks 52 and 104<sup>1,2</sup>
> PATIENTS (%)
> Co-primary endpoint
> 0
> 20
> 40
> 60
> 80
> 100
> WEEK 52
> WEEK 104
> 62%a
> 46%
> 59%a
> 43%
> HUMIRA 40 mg EOW + MTX (n=268)
> MTX (n=257)
>
> NRI analysis<sup>b</sup>
>
> <sup>a</sup>P<0.001
> <sup>b</sup>The analysis is of the intent-to-treat (ITT) population using nonresponder imputation (NRI) methodology. Patients who withdrew or had missing values were considered nonresponders.”

Source: [HUMIRA: HUMIRA® (adalimumab) for Rheumatoid Arthritis (RA), captured 2026-11-13](https://www.humirapro.com/rheumatoid-arthritis#:~:text=Signs%20and%20symptoms%3A%20ACR50%20response,missing%20values%20were%20considered%20nonresponders.)

> “Table 5. ACR Response in Study RA-V (Percent of Subjects) 
> Response 
> MTX<sup>b</sup> 
> N=257 
> HUMIRA<sup>c</sup> 
> N=274 
> HUMIRA/MTX 
> N=268 
> ACR20 
>     Week 52 
>     Week 104  
>
> 63% 
> 56%  
>
> 54% 
> 49%  
>
> 73% 
> 69%  
> ACR50 
>     Week 52 
>     Week 104  
>
> 46% 
> 43%  
>
> 41% 
> 37%  
>
> 62% 
> 59%  
> ACR70 
>     Week 52 
>     Week 104  
>
> 27% 
> 28%  
>
> 26% 
> 28%  
>
> 46% 
> 47%  
> Major Clinical Response <sup>a</sup> 
> 28% 
> 25% 
> 49% 
> <sup>a</sup> Major clinical response is defined as achieving an ACR70 response for a continuous six month 
> period 
> <sup>b</sup> p<0.05, HUMIRA/MTX vs. MTX for ACR 20 
> p<0.001, HUMIRA/MTX vs. MTX for ACR 50 and 70, and Major Clinical Response 
> <sup>c</sup> p<0.001, HUMIRA/MTX vs. HUMIRA”

Source: [HUMIRA: Prescribing information, page 35, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=35)

Note: PREMIER is the trial the Prescribing Information calls Study RA-V. Table 5 columns are MTX, HUMIRA, and HUMIRA/MTX, in that order.

<a id="humira-premier-joint-damage"></a>

### Does Humira plus methotrexate slow joint damage in early RA (PREMIER)?

Applies to: Adults with early moderate to severe rheumatoid arthritis (less than 3 years' duration) who had not received methotrexate (PREMIER, Study RA-V)

> “Radiographic progression: joint damage through 2 years
> Mean change from baseline mTSS at Year 1 and 2<sup>1,2</sup>
> MEAN CHANGE FROM BASELINE
> 0
> 2
> 4
> 6
> 8
> 10
> 12
> YEAR 1
> YEAR 2
> 5.7
> 10.4
> 1.3a
> 1.9b
> HUMIRA 40 mg EOW + MTX (n=268)
> MTX (n=257)
>
> Extrapolated analysis<sup>c</sup>
>
> <sup>a</sup>P<0.002 HUMIRA + MTX vs MTX
> <sup>b</sup>P<0.001 HUMIRA + MTX vs MTX
> <sup>c</sup>Analysis of the intent-to-treat (ITT) study population. Values for missing data were imputed by a predefined linear progression method.”

Source: [HUMIRA: HUMIRA® (adalimumab) for Rheumatoid Arthritis (RA), captured 2026-11-13](https://www.humirapro.com/rheumatoid-arthritis#:~:text=Radiographic%20progression%3A%20joint%20damage%20through,a%20predefined%20linear%20progression%20method.)

> “In Study RA-V, structural joint damage was assessed as in Study RA-III. Greater inhibition of 
> radiographic progression, as assessed by changes in TSS, erosion score and JSN was observed in 
> the HUMIRA/MTX combination group as compared to either the MTX or HUMIRA 
> monotherapy group at Week 52 as well as at Week 104 (see Table 7).  
> Table 7.  Radiographic Mean Change* in Study RA-V 
>
>
> MTX<sup>a</sup> 
> N=257 
> HUMIRA<sup>a,b</sup> 
> N=274 
> HUMIRA/MTX 
> N=268 
> 52 Weeks 
> Total Sharp score 
> 5.7 (4.2, 7.3) 
> 3.0 (1.7, 4.3) 
> 1.3 (0.5, 2.1) 
>
> Erosion score 
> 3.7 (2.7, 4.8) 
> 1.7 (1.0, 2.4) 
> 0.8 (0.4, 1.2) 
>
> JSN score 
> 2.0 (1.2, 2.8) 
> 1.3 (0.5, 2.1) 
> 0.5 (0.0, 1.0) 
> 104 Weeks 
> Total Sharp score 
> 10.4 (7.7, 13.2) 
> 5.5 (3.6, 7.4) 
> 1.9 (0.9, 2.9) 
>
> Erosion score 
> 6.4 (4.6, 8.2) 
> 3.0 (2.0, 4.0) 
> 1.0 (0.4, 1.6) 
>
> JSN score 
> 4.1 (2.7, 5.4) 
> 2.6 (1.5, 3.7) 
> 0.9 (0.3, 1.5) 
> *  mean (95% confidence interval) 
> <sup>a</sup>  p<0.001, HUMIRA/MTX vs. MTX at 52 and 104 weeks and for HUMIRA/MTX vs. 
> HUMIRA at 104 weeks 
> <sup>b</sup>  p<0.01, for HUMIRA/MTX vs. HUMIRA at 52 weeks”

Source: [HUMIRA: Prescribing information, page 36, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=36)

Note: The site labels the whole chart as an extrapolated analysis (footnote c). Table 7 columns are MTX, HUMIRA, and HUMIRA/MTX, in that order.

<a id="humira-ra-joint-damage-with-mtx"></a>

### Does Humira with methotrexate slow joint damage in established RA (Study RA-III)?

> “In Study RA-III, structural joint damage was assessed radiographically and expressed as change 
> in Total Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing 
> (JSN) score, at month 12 compared to baseline. At baseline, the median TSS was approximately 
> 55 in the placebo and 40 mg every other week groups. The results are shown in Table 6. 
> HUMIRA/MTX treated subjects demonstrated less radiographic progression than subjects 
> receiving MTX alone at 52 weeks.  
> Table 6. Radiographic Mean Changes Over 12 Months in Study RA-III 
>
> Placebo/MTX HUMIRA/MTX 
> 40 mg every 
> other week  
> Placebo/MTX- 
> HUMIRA/MTX (95% Confidence 
> Interval*)  
> P-value** 
> Total Sharp score 
> 2.7 
> 0.1 
> 2.6 (1.4, 3.8) 
> <0.001 
> Erosion score 
> 1.6 
> 0.0 
> 1.6 (0.9, 2.2) 
> <0.001 
> JSN score 
> 1.0 
> 0.1 
> 0.9 (0.3, 1.4) 
> 0.002 
> *95% confidence intervals for the differences in change scores between MTX and HUMIRA.  
> **Based on rank analysis”

Source: [HUMIRA: Prescribing information, page 35, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=35)

> “In the open-label extension of Study RA-III, 77% of the original subjects treated with any dose 
> of HUMIRA were evaluated radiographically at 2 years. Subjects maintained inhibition of 
> structural damage, as measured by the TSS. Fifty-four percent had no progression of structural”

Source: [HUMIRA: Prescribing information, page 35, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=35)

> “damage as defined by a change in the TSS of zero or less. Fifty-five percent (55%) of subjects 
> originally treated with 40 mg HUMIRA every other week have been evaluated radiographically 
> at 5 years. Subjects had continued inhibition of structural damage with 50% showing no 
> progression of structural damage defined by a change in the TSS of zero or less.”

Source: [HUMIRA: Prescribing information, page 36, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=36)

Note: The last two passages are one paragraph that continues from page 35 to page 36 of the Prescribing Information. Study RA-III enrolled subjects with an inadequate response to methotrexate.

<a id="humira-premier-remission"></a>

### What remission rates did Humira plus methotrexate reach in early RA (PREMIER)?

Applies to: Adults with early moderate to severe rheumatoid arthritis (less than 3 years' duration) who had not received methotrexate (PREMIER, Study RA-V)

> “Additional measures: clinical remission at 1 and 2 years<sup>2,*</sup>
> Percent of patients meeting response criterion DAS28 <2.6
> PATIENTS (%)
> 0
> 10
> 20
> 30
> 40
> 50
> YEAR 1
> YEAR 2
> 43%a
> 21%
> 49%
> 25%
> HUMIRA 40 mg EOW + MTX (n=268)
> MTX (n=257)
>
> <sup>a</sup>P<0.001”

Source: [HUMIRA: HUMIRA® (adalimumab) for Rheumatoid Arthritis (RA), captured 2026-11-13](https://www.humirapro.com/rheumatoid-arthritis#:~:text=Additional%20measures%3A%20clinical%20remission%20at,MTX%20%28n%3D257%29)

> “Clinical remission does not mean drug-free remission or complete absence of disease activity.
>
> DATA LIMITATION
>
> Clinical remission at Year 2 was not a pre-specified endpoint and was not controlled for multiplicity. This data cannot be regarded as statistically or clinically significant, and therefore, no conclusions can be drawn.
>
> <sup>*</sup>Clinical remission at Year 1 was a secondary endpoint and was defined as DAS28 <2.6. Disease activity score (DAS) is a composite index that includes variables such as the number of tender and swollen joints and either erythrocyte sedimentation rate or C-reactive protein (CRP) and may include the patient’s assessment of disease activity.”

Source: [HUMIRA: HUMIRA® (adalimumab) for Rheumatoid Arthritis (RA), captured 2026-11-13](https://www.humirapro.com/rheumatoid-arthritis#:~:text=Clinical%20remission%20does%20not%20mean,patient%E2%80%99s%20assessment%20of%20disease%20activity.)

<a id="humira-ra-physical-function"></a>

### Does Humira improve physical function (HAQ-DI) in rheumatoid arthritis?

> “In studies RA-I through IV, HUMIRA showed significantly greater improvement than placebo in 
> the disability index of Health Assessment Questionnaire (HAQ-DI) from baseline to the end of 
> study, and significantly greater improvement than placebo in the health-outcomes as assessed by 
> The Short Form Health Survey (SF 36). Improvement was seen in both the Physical Component 
> Summary (PCS) and the Mental Component Summary (MCS).  
> In Study RA-III, the mean (95% CI) improvement in HAQ-DI from baseline at week 52 was 
> 0.60 (0.55, 0.65) for the HUMIRA subjects and 0.25 (0.17, 0.33) for placebo/MTX (p<0.001) 
> subjects. Sixty-three percent of HUMIRA-treated subjects achieved a 0.5 or greater improvement 
> in HAQ-DI at week 52 in the double-blind portion of the study. Eighty-two percent of these 
> subjects maintained that improvement through week 104 and a similar proportion of subjects 
> maintained this response through week 260 (5 years) of open-label treatment. Mean 
> improvement in the SF-36 was maintained through the end of measurement at week 156 (3 
> years).  
> In Study RA-V, the HAQ-DI and the physical component of the SF-36 showed greater 
> improvement (p<0.001) for the HUMIRA/MTX combination therapy group versus either the 
> MTX monotherapy or the HUMIRA monotherapy group at Week 52, which was maintained 
> through Week 104.”

Source: [HUMIRA: Prescribing information, page 36, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=36)

## Long-term results

<a id="humira-ra-long-term-response"></a>

### Do Humira responses last long term in rheumatoid arthritis?

> “ACR response rates and improvement in all components of ACR response 
> were maintained to week 104. Over the 2 years in Study RA-III, 20% of HUMIRA subjects 
> receiving 40 mg every other week achieved a major clinical response, defined as maintenance of 
> an ACR 70 response over a 6-month period. ACR responses were maintained in similar 
> proportions of subjects for up to 5 years with continuous HUMIRA treatment in the open-label 
> portion of Study RA-III.”

Source: [HUMIRA: Prescribing information, page 33, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=33)

> “In Study RA-III, 85% of subjects with ACR 20 responses at week 24 maintained the response at 
> 52 weeks.”

Source: [HUMIRA: Prescribing information, page 34, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=34)

## Related pages
- [Medical information: Humira (adalimumab): Rheumatoid arthritis](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis)
- [Indication](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/access-and-coverage)
